Skip to main content Skip to main menu
University of Florida Health University of Florida
Cancer Center
Contact Us: (352) 273-8010
Research Overview

National Cancer Institute

TitleKeywordsActivity CodeFOALOI Due DateApplication Due Date
(NOSI): Research on HIV - associated MalignanciesSocial, behavioral , communication, education, strategies, prevention, early detection, treatmentR21,R01NOT-CA-23-0709/7/2026
(NOSI): National Cancer Institute Entrepreneurial Education Programs to Facilitate Commercialization of Cancer Relevant TechnologiesSocial determinants, SDOH, evaluating interventionsR25NOT-CA-24-0011/7/2027
(NOSI): Epidemiologic Studies to Assess the Impact of Incretin Mimetics on New and Recurrent Cancer Riskepidemiology R00, R01, R21, K08, K22, K99, NOT-CA-24-0375/9/2026
Dissemination and Implementation Research in Health (R21 Clinical Trial Optional)Dissemination, implementationR21PAR-25-1435/17/20256/16/2025
NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)Clinical Trials, Early-stage, diagnosis, precention, molecules, xenograft, biology, ESIR21PAR-25-1396/12/2025
(NOSI): Research Projects to Develop Oncoaging Models for Cancer ResearchEquity, equitable care, interventionsR21,R01NOT-CA-23-0927/30/2027
Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R21 Clinical Trials Not Allowed)Health Equity Research, Specifically named cancers (Various Cancer Types), Community ExposuresR21PAR-25-0966/18/0275
Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Optional)Health Equity Research, Specifically named cancers (Various Cancer Types), Community ExposuresR21PAR-25-3216/16/2025
Academic - Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Not Allowed)Health Equity Research, Specifically named cancers (Various Cancer Types), Community ExposuresR01PAR-25-3386/5/2025
Imaging, Biomarkers and Digital Pathomics for the Early Detection of Premetastatic Cancer and Precancerous Lesions Associated with Lethal Phenotypes (R01 Clinical Trial Optional)Phenotype, biomarkers, premastatic R01PAR-22-1316/5/2025
The NCI Transition Career Development Award (K22 Independent Clinical Trial Optional)cancer research, tenure-track faculty position, mentored research training, career development, clinical trialsK22PAR-24-1176/12/2025
(NOSI): Basic Mechanisms of Cannabis and Cannabinoid Action in CancerCannabis, cannabinoids, interception, therapeutic applications, biologyK22,R01,K08,K01,R21,R03,K99/R00NOT-CA-22-0857/4/2027
(NOSI): Utilization of Cohorts and Prospective Study Designs for Liquid Biopsy Assay Validation for Early Detection of CancersEarly detection, Advanced biomarkers, High-risk individuals, early detectionR43/R44,R21,R01,UH2/UH3,R41/R42,U01NOT-CA-23-0047/1/2025
(NOSI): Adaptive Biomaterials for Cancer BiologyAdaptive biomaterials, Biology, biomaterials, diagnostic, therapeuticR01,K22,K99/R00NOT-CA-23-0305/6/2025
(NOSI): RNA Modifications in Cancer BiologyPrecision prevention, AI, high risk, prevention strategiesR33,R21,U01,R61,R03NOT-CA-23-0601/7/2026
(NOSI): Exploratory Cancer Immunology Projects and Technologies (ExCITe)Clinical decision support tools, CDSTs, care delivery, clinical decision-making, patient outcomesR21NOT-CA-24-01611/16/2026
(NOSI): National Cancer Institute Supports Applications for the Mentored Research Scientist Development Awards (K01) Within the Mission of the Division of Cancer Control and Population SciencesMentored Research, Development Awards, Population Sciences, susceptibility factors, genetic, epigenetic, immunological, inflammatory, hormonal, social, cultural, ethnic, Intervention development, obacco, alcohol, diet, physical activity, behavioral, psychosocialK01NOT-CA-24-0225/7/2029
(NOSI): National Cancer Institute Supports Applications for the Mentored Research Scientist Development Awards (K01) Within the Mission of the Division of Cancer PreventionMentored Research, Development Awards, Down syndromeK01NOT-CA-24-0235/7/2029
The NCI Worta McCaskill - Stevens Career Development Award for Community Oncology and Prevention Research (K12 Clinical Trial Optional)Community oncology, Cancer prevention research, Career development, Clinical trials, early career K12PAR-24-1536/18/2025
(NOSI): Advancing Diet and Physical Activity Biomarkers for Assessing Lifestyle Interventions in Cancer Prevention and Cancer Interception ResearchPrevention, diet, interceptionNOT-CA-24-0601/8/2027
Precision Approaches in Radiation Synthetic Combinations (PAIRS, R21 Clinical Trial Optional)Radiation therapy, pre-clinical, clinical trialsR21PAR-22-1995/17/20256/16/2025
(NOSI): Dissemination and Implementation Science for Cancer Prevention and Control in Low Resource EnvironmentsCommunity, prevention, implementationR01, R03, R21NOT-CA-24-0641/8/2028
(NOSI): Advancing Diet and Physical Activity Biomarkers for Assessing Lifestyle Interventions in Cancer Prevention and Cancer Interception Researchbiomarkers, lifestyle interventions, prevention, interception, diet, physical activityR01, R03, R21NOT-CA-24-0741/8/2027
Mechanisms that Impact Cancer Risk after Bariatric Surgery (R21 Clinical Trial Not Allowed)Investigator-Initiated Research, surgery, early-stagePAR-25-0445/17/20256/16/2025
Mechanisms that Impact Cancer Risk after Bariatric Surgery (R01 Clinical Trial Optional)Investigator-Initiated Research, surgery, R01PAR-25-0435/6/20256/5/2025
(NOSI): Career Development Opportunities for Research on Cancer in Global Settings at the Center for Global Health at the National Cancer InstituteTraining, Global Health, international, collaboration, (LMICs)K01, K08, K99, R00, R25NOT-CA-24-0985/8/2027
Bioengineering Research Grants (BRG) (R01 Clinical Trial Not Allowed)technology development, innovationR01PAR-22-2426/5/2025
Bioengineering Research Grants (BRG) (R01 Clinical Trial Optional)technology development, clinical translation, innovationR01PAR-22-2435/6/20256/5/2025
Cancer Prevention Clinical Trials Network (CP-CTNet): Data Management, Auditing, and Statistical Center (DMASC) (UG1 Clinical Trial Required)prevention, clinical trials, network, data management, biostatisticsUG1RFA-CA-24-02510/1/202410/31/2024
National Cancer Institute Program Project Applications for the Years 2023, 2024, and 2025 (P01 Clinical Trial Optional)multi-investigator, collaborative, multidisciplinary, large-scaleP01PAR-23-0594/25/20255/25/2025
(NOSI): Telehealth Research in Cancer Caretelehealth, digital health, remote monitoring, telemedicine, access to care, virtual careR01, R03, R21NOT-CA-24-0333/17/2026
Precision Approaches in Radiation Synthetic Combinations (PAIRS, R01 Clinical Trial Optional)radiation therapy, drug combinations, radiosensitizers, precision medicine, personalized medicineR01PAR-22-1985/6/20256/5/2025
Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed)molecular, biomarkers, therapies, clinical UH2, UH3PAR-25-0746/11/2025
Co-infection and Cancer (R01 Clinical Trial Not Allowed)infectious diseases, viruses, bacteria, HIV, HPVR01PAR-25-0826/5/2025
Revision Applications for Validation of Biomarker Assays Developed Through NIH-Supported Research Grants (R01 Clinical Trial Not Allowed)biomarkers, assay validation, assay development, translational, diagnosticsR01PAR-24-3047/11/2025
The Metastasis Research Network (MetNet): MetNet Research Projects (U01 Clinical Trial Not Allowed)Systems-level, mechanisms of responses. Therapy, novel, data, collaborativeU01PAR-25-1305/21/20256/20/2025
Dissemination and Implementation Research in Health (R01 Clinical Trial Optional)dissemination, implementation, evidence-based interventions, publicR01PAR-25-1445/6/20256/5/2025
Dissemination and Implementation Research in Health (R03 Clinical Trial Not Allowed)dissemination, implementation, evidence-based interventionsR03PAR-25-2335/17/20256/16/2025
Modular R01s in Cancer Control and Population Sciences (R01 Clinical Trial Optional)Cancer Control, Population Sciences, Clinical TrialR01PA-25-1726/5/2025
Cancer Prevention and Control Clinical Trials Planning Grant Program (U34 Clinical Trials Optional)preventative, clinical trials, planning, pilot studiesU34PAR-25-1035/26/20256/25/2025
Cancer Prevention and Control Clinical Trials Planning Grant Program (R34 Clinical Trials Optional)preventative, clinical trials, planning, feasibility studiesR34PAR-25-1045/26/20256/25/2025
Exploratory Grants in Cancer Control (R21 Clinical Trial Optional)Exploratory, Early-stage, cancer control, novel, ESIR21PA-25-2535/17/20256/16/2025
Research Projects to Enhance Applicability of Mammalian Models for Translational Research (R01 Clinical Trial Not Allowed)Animal models, Translational research, R01PAR-24-3066/5/2025
Molecular Imaging of Inflammation in Cancer (R01 Clinical Trial Not Allowed)cancer imaging, inflammation, molecular imaging, PET, MRI, biomarkers, diagnosis, prognosisR01PAR-24-3115/6/20256/5/2025
Academic - Industrial Partnerships (AIP) to Translate and Validate In Vivo Imaging Systems (R01 Clinical Trial Optional)Biomedical Imaging, In Vivo Imaging, Cancer Detection, Medical Technology, LimitedPAR-25-0796/5/2025
Co - infection and Cancer (R21 Clinical Trial Not Allowed)Co-infection, epidemiology, mechanistic studiesR21PAR-25-0835/17/20256/16/2025
Innovative Research in Cancer Nanotechnology (IRCN; R01 Clinical Trial Not Allowed)Nanotechnology, Brain Disorders, Biomedical Systems, BiomarkersR01PAR-25-1065/5/2025
Clinical Characterization of Cancer Therapy - induced Adverse Sequelae and Mechanism - based Interventional Strategies (R01 Clinical Trial Optional)collaborative, therapies, basic, translational, clinical, biomarkers, R01PAR-25-1455/6/20256/5/2025
Assay development and screening for discovery of chemical probes, drugs or immunomodulators (R01 Clinical Trial Not Allowed)chemical probes, drug discovery, immunomodulators, high-throughput screening, assay developmentR01PAR-25-1535/6/20256/5/2025
Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy (R01 Clinical Trial Optional)tumor, imagingR01PAR-25-1755/6/20256/5/2025
Population Approaches to Reducing Alcohol-related Cancer Risk (R01 Clinical Trial Optional)alcohol, risk reduction, prevention, public health, behavioral interventions, epidemiologyR01PAR-25-2216/5/2025
Biology of Bladder Cancer (R01 Clinical Trial Optional)biology, genetics, novel interventions, R01PAR-25-1295/6/20256/5/2025
Biology of Bladder Cancer (R21 Clinical Trial Optional)Exploratory, biology, genetics, novel interventions, R21PAR-25-1285/17/20256/16/2025
NCI Pathway to Independence Award (K99/R00 – Clinical Trial Not Allowed)postdoctoral, transition, early career, career developmentK99, R00PAR-25-1356/17/2025
Innovative Approaches to Studying Cancer Communication in the New Information Ecosystem (R01 Clinical Trial Optional)health communication, digital health, social media, misinformation, health literacyR01PA-25-2946/5/2025
Innovative Approaches to Studying Cancer Communication in the New Information Ecosystem (R21 Clinical Trial Optional)Communication, social media, online tools, health information, publicR21PA-25-2956/16/2025
Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research (U01 Clinical Trial Not Allowed)epidemiological studiesU01PAR-25-2485/11/20256/10/2025
Understanding Expectancies in Cancer Symptom Management (R01 Clinical Trial Required)Nanotechnology, Brain Disorders, Biomedical Systems, BiomarkersR01PAR-25-2546/5/2025
(NOSI): Dissemination and Implementation Science for Cancer Prevention and Control in Low Resource Environmentsprevention, controlR01, R03, R21NOT-CA-25-0121/8/2028
High-Priority Research in Tobacco Regulatory Science (R01 Clinical Trial Optional)tobacco regulatory science, addiction, behavior, health effects, product composition, design, toxicityR01RFA-OD-25-0014/6/20256/6/2025
National Cancer Institute's Investigator - Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required)clinical trials, early phase, treatment, diagnosis, innovative therapiesR01PAR-25-0815/6/20256/5/2025
Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R01 Clinical Trial Not Allowed)Nanotechnology, Brain Disorders, Biomedical Systems, BiomarkersR01PAR-25-0956/5/2025
NCMRR Early Career Research Award (R03 Clinical Trial Optional)Biomedical Informatics, Cancer Informatics, Health Data Management, Cancer ResearchR03PAR-25-1246/18/0275
Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R01 Clinical Trial Optional)Mechanisms, Cancer risk, Incretin mimetics, Clinical trial optionalR01PAR-25-0695/6/20256/5/2025
Impacts of climate change across the cancer control continuum (R01 Clinical Trial Optional)environmental health, exposures, continuum of careR01PAR-25-0945/6/20256/5/2025
Pragmatic Trials across the Cancer Control Continuum (UG3/UH3 Clinical Trial Required)implementation, health services, continuum of care, patient-centered outcomesUG3, UH3PAR-25-0725/15/20256/14/2025
Small Research Grants for Analyses of Gabriella Miller Kids First Pediatric Research Data (R03 Clinical Trial Not Allowed)Pediatric, birth defects, data analysis, geneticR03PAR-25-1096/18/0275
Discovery and Development of Natural Products for Cancer Interception and Prevention (UG3/UH3 Clinical Trial Not Allowed)natural products, interception, chemopreventionUG3, UH3RFA-CA-25-0135/14/20256/13/2025
Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Not Allowed)Bioengineering, biomedical, technology, innovative solutions, feasibility studiesR21PAR-25-3466/16/2025
Integrating Biospecimen Science Approaches into Clinical Assay Development (U01 Clinical Trial Not Allowed)Clinical, biology, biomarker, clinicalU01PAR-25-3255/5/20256/4/2025
(NOSI): NCI's Interest in Research on Interprofessional Teamwork and Coordination During Cancer Diagnosis and Treatmentmultidisciplinary, collaborationNOT-CA-25-0071/8/2028
(NOSI): Survivorship Research for People Living with Advanced and Metastatic Cancerspalliative, quality-of-life, psychosocialNOT-CA-25-0241/8/2028
(NOSI): Communication and Decision-Making in a Complex and Dynamic Cancer Treatment Environmentenvironment, patient-providerNOT-CA-25-0069/8/2028
Toward Translation of Nanotechnology Cancer Interventions (TTNCI) (R01 Clinical Trial Not Allowed)Biomedical Informatics, Cancer Informatics, Health Data Management, Cancer ResearchR01PAR-25-3365/19/2025
Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)molecular analysis, cellular analysis, technology development, validation, diagnostics, therapeutics, drug development, precision medicineR33RFA-CA-25-0023/5/20254/4/2025
Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)biospecimen science, technology development, validation, biobanking, tissue preservation, biomarkers, precision medicineR33RFA-CA-25-0043/5/20254/4/2025
Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)biospecimens, biobanking, tissue preservation, biomarkers, genomics, proteomics, precision medicineR61RFA-CA-25-0033/5/20254/4/2025
Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)molecular analysis, cellular analysis, diagnostics, therapeutics, drug development, precision medicine, nanotechnologyR61RFA-CA-25-0013/5/20254/4/2025
(NOSI): Mechanisms Driving Obesity and Prostate Cancer Riskprostate, risk, preventionR00, R01, R21, K99NOT-CA-25-0021/8/2028
(NOSI): Research on rare cancers across the cancer control continuumtreatment, diagnosis, epidemiologyR01, R03, R21, R34, U34, P01NOT-CA-25-0101/8/2028
Academic - Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Optional)Nanotechnology, Brain Disorders, Biomedical Systems, BiomarkersR01PAR-25-3376/5/2025
Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (R01 Clinical Trial Optional)Novel, Technology, Acceleration, Clinical TrialR01RFA-CA-25-0053/5/20254/4/2025
Revision Applications for Incorporation of Novel NCI- Supported Technology to Accelerate Cancer Research (U01 Clinical Trial Optional)Novel, Technology, Acceleration, Clinical TrialU01RFA-CA-25-0063/5/20254/4/2025
Method to Extend Research in Time (MERIT) Award Extension Request (Type 4 Clinical Trial Optional)Early-stage, innovation, ESI R37PAR-25-3247/1/2025
NCI Pathway to Independence Award (K99/R00 – Clinical Trial Required)early career researchers, career development, mentorship, clinical, trainingK99, R00PAR-25-3136/17/2025

Can’t find what you’re looking for? Please contact researchdevelopment@cancer.ufl.edu for assistance in finding additional funding opportunities.

NCI Cancer Center badge